Blood test to find early signs of a transplant complication
Part of Blood & lymphatic clinical trials.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer or serious blood disorder (like leukemia or lymphoma).
- You have received or will receive a stem cell transplant from a donor.
- You are 14 years old or older.
- You or a family member can sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how two immune system proteins, interferon and complement, are involved in a rare condition called thrombotic microangiopathy (TMA) that can damage small blood vessels after a stem cell or organ transplant. Understanding these proteins may help doctors find better treatments for TMA and related complications.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This study tracks patients who receive a stem cell transplant from a donor to see how often they develop a blood condition called transplant-associated thrombotic microangiopathy (TA-TMA). The goal is to identify patients at higher risk and monitor them closely for this condition.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Hear when a new Thrombotic Microangiopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.